Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 20 other studies
3,229people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
statins
placebo
Lowered end of treatment average total cholesterol−42.3
No clear effect on deaths1.3×
No clear effect on cardiovascular deaths−32%
randomisedthe abstract, start to end
… all-cause mortality (14 studies: RR 1.30, 95% CI 0.54 to 3.12).
… cardiovascular mortality (13 studies: RR 0.68, 95% CI 0.46 to 1.03) and non-fatal cardiovascular events (1 study: RR 0.70, 95% CI 0.48 to 1.01), however …
… total cholesterol (10 studies: MD -42.33 mg/dL (1.26 mmol/L), 95% CI …
← favours treatmentfavours comparator →
could be chanceAll-cause mortalitystatins vs placebo
RR 1.300.54–3.12
Cardiovascular mortalitystatins vs placebo
RR 0.680.46–1.03
Cardiovascular events
RR 0.700.48–1.01
End of treatment average total cholesterolstatins vs placebo
−42.33−53.0 to −31.6
StatinsLipidsCardiovascular eventsAll-cause mortality
Statins × cardiovascular eventshelps?replicated
unlikelylikely
0.86not counted
Statins × all-cause mortalityhelps?mixed
unlikelylikely
0.50not counted
Statins × lipidshelps?mixed
unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
1 / 6